FDA fast-tracks new Gleevec use

Earlier this week, Novartis got FDA priority review for Gleevec, its cancer med, for treatment of gastrointestinal stromal tumors after surgery. The agency will say "yea" or "nay" on the new indication within six months, rather than the typical 10. According to Novartis research, Gleevec cut the risk of tumors returning after surgery by 89 percent. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.